You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,518,720


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,518,720
Title: Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
Abstract:Methods of in vivo diagnosis and treatment for complications of diabetes are provided. Antibodies or other mimetic molecules which specifically bind to glycated albumin or its cellular receptor are administered to a human. Glycated albumin which retains a deoxyfructosyllysine moiety is found deposited at sites of diabetic tissue damage. Glycated albumin inhibits the growth of cells. Treatment with monoclonal anti-glycated albumin antibody reverses the growth inhibition caused by glycated albumin. In addition, glycated albumin stimulates the production of type IV collagen by kidney cells. Antibodies which bind to glycated albumin prevent the stimulation of type IV collagen production.
Inventor(s): Cohen; Margo P. (New York, NY)
Assignee: Exocell, Inc. (Philadelphia, PA)
Application Number:08/215,662
Patent Claims:1. A method of treating complications of diabetes which are caused by glycated albumin, comprising the steps of:

parenterally administering to a diabetic patient a therapeutic molecule which specifically binds the glycated albumin epitope bound by the monoclonal antibody produced by cell line ATCC HB 9596.

2. The method of claim 1 wherein the therapeutic molecule is a monoclonal antibody which specifically binds to an epitope present on glycated albumin but not present on non-glycated albumin or other human proteins.

3. The method of claim 2 wherein the antibody is A717 (produced by ATCC Deposit HB 9596).

4. The method of claim 1 wherein the patient has kidney disease.

5. The method of claim 4 wherein the therapeutic molecule is administered to an artery which serves the kidneys.

6. The method of claim 4 wherein the therapeutic molecule is administered in an amount sufficient to prevent deposition of glycated albumin in renal extracellular matrix of the patient.

7. The method of claim 4 wherein the patient has eye disease.

8. The method of claim 4 wherein the patient has vascular disease.

9. The method of claim 4 wherein the patient has nerve disease.

Details for Patent 5,518,720

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 10/21/1942 ⤷  Try a Trial 2013-05-21
Baxalta Us Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 03/03/1954 ⤷  Try a Trial 2013-05-21
Csl Behring Ag ALBURX albumin (human) Injection 102366 07/23/1976 ⤷  Try a Trial 2013-05-21
Grifols Biologicals Llc ALBUTEIN albumin (human) Injection 102478 08/15/1978 ⤷  Try a Trial 2013-05-21
Instituto Grifols, S.a. HUMAN ALBUMIN GRIFOLS albumin (human) Injection 103352 02/17/1995 ⤷  Try a Trial 2013-05-21
Instituto Grifols, S.a. HUMAN ALBUMIN GRIFOLS albumin (human) Injection 103352 06/11/2003 ⤷  Try a Trial 2013-05-21
Csl Behring Llc ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5 albumin (human) Injection 103955 03/17/2000 ⤷  Try a Trial 2013-05-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.